Categories Earnings, Health Care
Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot
— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.
— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected
— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year
— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine
— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer
— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020
— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
